The efficacy of anti-PD1 immunotherapy in glioma patients can be influenced by the tumor mutation burden (TMB), PD-L1 (CD274) expression, and tumor immune microenvironment cell components(TICC) (35–38). The gene discussed is PDCD1; the disease is glioma.